DEA Advances Psilocybin Rescheduling Petition to HHS for Scientific Review
The DEA's decision to forward psilocybin rescheduling for scientific review marks a significant regulatory shift that could expand medical access for veterans and palliative care patients while accelerating psychedelic research.
The U.S. Drug Enforcement Administration has taken a crucial step toward potential psilocybin rescheduling by forwarding a petition to the Department of Health and Human Services for scientific evaluation. This regulatory milestone represents significant progress in the decades-long effort to integrate psychedelics into mainstream medicine, with Psylutions, Colorado's first licensed regulated cultivator and manufacturer of psilocybin, welcoming the development as a long-overdue alignment between policy and scientific evidence.
Rhonda DeSantis, founder of Psylutions, emphasized the importance of this decision, stating that it brings healing one step closer to those who need it most. The company has positioned itself to help build a future where psilocybin therapy is safe, regulated, and accessible through its licensed cultivation, precision dosing, and partnership network already established in Colorado. If psilocybin is moved from Schedule I to Schedule II of the Controlled Substances Act, patients in palliative care and veterans suffering from PTSD would be among the first to benefit through expanded pathways like Right to Try legislation.
Henry Baskerville, General Counsel and Partner at Psylutions, described this development as signaling a regulatory awakening, noting that as agencies begin engaging with medical evidence over stigma, the industry is entering a watershed moment for psychedelics. He believes psychedelics hold even greater potential for significant medical applications than cannabis, emphasizing the critical need to approach this transition with the highest standards. The company has invested heavily in infrastructure to meet rigorous safety requirements, including strain optimization, lab-verified dosing, and triple HEPA filtration systems to mitigate contamination risk.
Psylutions currently partners with over 50% of healing centers operating across Colorado to provide regulated psilocybin solutions for chronic pain, trauma relief, end-of-life care, and broader mental wellness. The rescheduling would not only benefit patients but also accelerate research opportunities and expand access for clinicians and licensed healing centers. DeSantis added that as soon as psilocybin is rescheduled from Schedule I, patients facing terminal illness and veterans at risk of suicide will finally have safe, legal access through Right to Try provisions, with Psylutions committed to ensuring that access is built on medicine that is effective, rigorously verified, and responsibly produced. Learn more at https://thepsylutions.com.